

Rocio Herrero Vanrell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2281738/publications.pdf>

Version: 2024-02-01

89
papers

2,850
citations

147801

31
h-index

189892

50
g-index

97
all docs

97
docs citations

97
times ranked

3119
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce <i>in vitro</i> hyperosmolar stress in dry eye treatments. <i>Journal of Liposome Research</i> , 2023, 33, 117-128.	3.3	2
2	Validation of a Rapid and Easy-to-Apply Method to Simultaneously Quantify Co-Loaded Dexamethasone and Melatonin PLGA Microspheres by HPLC-UV: Encapsulation Efficiency and In Vitro Release. <i>Pharmaceutics</i> , 2022, 14, 288.	4.5	8
3	Design, optimization, and in vitro characterization of idebenone-loaded PLGA microspheres for LHON treatment. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121504.	5.2	10
4	Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2434.	4.1	50
5	Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection. <i>International Journal of Pharmaceutics</i> , 2022, 623, 121948.	5.2	3
6	Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment. <i>Pharmaceutics</i> , 2022, 14, 1405.	4.5	4
7	Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1-29.	5.0	36
8	A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies. <i>Pharmaceutics</i> , 2021, 14, 50.	3.8	9
9	Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies. <i>Pharmaceutics</i> , 2021, 13, 228.	4.5	16
10	Thermo-Responsive PLGA-PEG-PLGA Hydrogels as Novel Injectable Platforms for Neuroprotective Combined Therapies in the Treatment of Retinal Degenerative Diseases. <i>Pharmaceutics</i> , 2021, 13, 234.	4.5	24
11	Novel Use of PLGA Microspheres to Create an Animal Model of Glaucoma with Progressive Neuroretinal Degeneration. <i>Pharmaceutics</i> , 2021, 13, 237.	4.5	11
12	Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases. <i>Drug Delivery and Translational Research</i> , 2021, 11, 566-580.	5.8	8
13	The Effect of a Triple Combination of Bevacizumab, Sodium Hyaluronate and a Collagen Matrix Implant in a Trabeculectomy Animal Model. <i>Pharmaceutics</i> , 2021, 13, 896.	4.5	3
14	Chronic Glaucoma Using Biodegradable Microspheres to Induce Intraocular Pressure Elevation. Six-Month Follow-Up. <i>Biomedicines</i> , 2021, 9, 682.	3.2	13
15	Influence of Chronic Ocular Hypertension on Emmetropia: Refractive, Structural and Functional Study in Two Rat Models. <i>Journal of Clinical Medicine</i> , 2021, 10, 3697.	2.4	1
16	Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy. <i>Diabetes</i> , 2021, 70, 2668-2682.	0.6	14
17	Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments. <i>Experimental Eye Research</i> , 2021, 211, 108723.	2.6	12
18	Influence of Sex on Neuroretinal Degeneration: Six-Month Follow-Up in Rats With Chronic Glaucoma. , 2021, 62, 9.		7

#	ARTICLE	IF	CITATIONS
19	Analysis of Parainflammation in Chronic Glaucoma Using Vitreous-OCT Imaging. <i>Biomedicines</i> , 2021, 9, 1792.	3.2	5
20	Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres. <i>Drug Delivery</i> , 2021, 28, 2427-2446.	5.7	7
21	Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents. <i>Pharmaceutics</i> , 2020, 12, 306.	4.5	23
22	Trojan Microparticles Potential for Ophthalmic Drug Delivery. <i>Current Medicinal Chemistry</i> , 2020, 27, 570-582.	2.4	4
23	Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers. <i>Polymers</i> , 2019, 11, 1213.	4.5	6
24	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. <i>Nature Communications</i> , 2019, 10, 369.	12.8	47
25	Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. <i>Journal of Controlled Release</i> , 2019, 297, 26-38.	9.9	57
26	Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment. <i>Polymers</i> , 2019, 11, 929.	4.5	20
27	Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases. <i>Drug Discovery Today</i> , 2019, 24, 1644-1653.	6.4	18
28	Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1655.	4.1	19
29	Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina. <i>Advanced Drug Delivery Reviews</i> , 2018, 126, 127-144.	13.7	28
30	Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation. <i>Experimental Eye Research</i> , 2018, 167, 118-121.	2.6	7
31	Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. <i>Contact Lens and Anterior Eye</i> , 2018, 41, 93-96.	1.7	41
32	Design and Application of a Computer Tool to Evaluate the Goodness of Fit for Tests Designed to Be Self-Taught. <i>Proceedings (mdpi)</i> , 2018, 2, .	0.2	0
33	Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film. <i>Polymers</i> , 2018, 10, 425.	4.5	28
34	Novel liposomal artificial tear formulation containing gellan gum for dry eye disease treatment. <i>Contact Lens and Anterior Eye</i> , 2018, 41, S77.	1.7	0
35	Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice. <i>Molecular Vision</i> , 2018, 24, 733-745.	1.1	15
36	Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 103, 19-26.	4.0	29

#	ARTICLE	IF	CITATIONS
37	Evaluation of polyestamide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats. <i>Biomaterials</i> , 2017, 124, 157-168.	11.4	37
38	Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma. <i>Advances in Therapy</i> , 2017, 34, 378-395.	2.9	37
39	Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. <i>Journal of Controlled Release</i> , 2017, 266, 187-197.	9.9	29
40	Novel technologies for the delivery of ocular therapeutics in glaucoma. <i>Journal of Drug Delivery Science and Technology</i> , 2017, 42, 181-192.	3.0	17
41	Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: InÂvivo and exÂvivo functionality studies in corneal epithelial cells. <i>Experimental Eye Research</i> , 2017, 154, 79-87.	2.6	12
42	Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats. <i>PLoS ONE</i> , 2017, 12, e0177998.	2.5	39
43	Ketorolac Administration Attenuates Retinal Ganglion Cell Death After Axonal Injury. , 2016, 57, 1183.		16
44	Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration. <i>Molecular Pharmaceutics</i> , 2016, 13, 2966-2976.	4.6	50
45	Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases. <i>Drug Delivery and Translational Research</i> , 2016, 6, 686-707.	5.8	27
46	Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 92, 287-297.	4.0	37
47	Block Copolypeptide Nanoparticles for the Delivery of Ocular Therapeutics. <i>Macromolecular Bioscience</i> , 2015, 15, 138-145.	4.1	7
48	Novel biodegradable polyestamide microspheres for controlled drug delivery in Ophthalmology. <i>Journal of Controlled Release</i> , 2015, 211, 105-117.	9.9	85
49	The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. <i>Progress in Retinal and Eye Research</i> , 2014, 42, 27-43.	15.5	96
50	Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 7839-7847.	3.3	42
51	Hybrid Formulations of Liposomes and Bioadhesive Polymers Improve the Hypotensive Effect of the Melatonin Analogue 5-MCA-NAT in Rabbit Eyes. <i>PLoS ONE</i> , 2014, 9, e110344.	2.5	29
52	Nano and microtechnologies for ophthalmic administration, an overview. <i>Journal of Drug Delivery Science and Technology</i> , 2013, 23, 75-102.	3.0	31
53	In vivo toxicity evaluation of mannitol included in freeze-dried PEA-III microparticles. <i>Acta Ophthalmologica</i> , 2013, 91, 0-0.	1.1	0
54	Effects of corneal thickness on the intraocular penetration of travoprost 0.004%. <i>Eye</i> , 2012, 26, 972-975.	2.1	6

#	ARTICLE	IF	CITATIONS
55	Recent Patents and Developments in Glaucoma Biomarkers. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 224-234.	0.6	6
56	Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation. International Journal of Pharmaceutics, 2012, 436, 545-554.	5.2	23
57	Interfacial Interaction between Transmembrane Ocular Mucins and Adhesive Polymers and Dendrimers Analyzed by Surface Plasmon Resonance. Pharmaceutical Research, 2012, 29, 2329-2340.	3.5	56
58	Random Co-Polymers Based on the Poloxamer Bayfit® 10WF15 for Biomedical Applications. Journal of Biomaterials Science, Polymer Edition, 2011, 22, 1895-1916.	3.5	3
59	Performance of the rebound, noncontact and Goldmann applanation tonometers in routine clinical practice. Acta Ophthalmologica, 2011, 89, 676-680.	1.1	38
60	The Use of Mucoadhesive Polymers to Enhance the Hypotensive Effect of a Melatonin Analogue, 5-MCA-NAT, in Rabbit Eyes. , 2011, 52, 1507.		21
61	Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive Polymers. , 2011, 52, 3548.		28
62	Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clinical Ophthalmology, 2011, 5, 139.	1.8	63
63	Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. Journal of Controlled Release, 2011, 156, 92-100.	9.9	89
64	Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials, 2011, 32, 1041-1050.	11.4	70
65	Microparticles as Drug Delivery Systems for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 231-259.	0.6	3
66	Comparative Analysis of Carmellose 0.5% Versus Hyaluronate 0.15% in Dry Eye: A Flow Cytometric Study. Cornea, 2010, 29, 167-171.	1.7	29
67	The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study. Eye, 2010, 24, 1331-1337.	2.1	67
68	Ocular pharmacokinetic, drug bioavailability, and intraocular drug delivery systems. , 2010, , 60-66.		6
69	Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. Expert Opinion on Drug Delivery, 2010, 7, 955-965.	5.0	10
70	Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Experimental Eye Research, 2009, 88, 504-511.	2.6	26
71	Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Experimental Eye Research, 2009, 89, 238-245.	2.6	65
72	Radiosterilisation of indomethacin PLGA/PEG-derivative microspheres: Protective effects of low temperature during gamma-irradiation. International Journal of Pharmaceutics, 2006, 313, 129-135.	5.2	42

#	ARTICLE	IF	CITATIONS
73	Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. International Journal of Pharmaceutics, 2006, 326, 100-106.	5.2	31
74	Biocompatibility of elastin-like polymer poly(VPAVG) microparticles:in vitro andin vivo studies. Journal of Biomedical Materials Research - Part A, 2006, 78A, 343-351.	4.0	86
75	Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release. Journal of Controlled Release, 2005, 102, 113-122.	9.9	211
76	Biodegradable Additives Modulate Ganciclovir Release Rate From PLGA Microspheres Destined to Intraocular Administration. Letters in Drug Design and Discovery, 2005, 2, 148-149.	0.7	8
77	Study of gamma-irradiation effects on aciclovir poly(d,l-lactic-co-glycolic) acid microspheres for intravitreal administration. Journal of Controlled Release, 2004, 99, 41-52.	9.9	68
78	Optimisation of aciclovir poly(?,?-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. International Journal of Pharmaceutics, 2004, 273, 45-56.	5.2	42
79	Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. International Journal of Pharmaceutics, 2004, 279, 33-41.	5.2	99
80	Sterilized ibuprofen-loaded poly(D,L-lactide-co-glycolide) microspheres for intra-articular administration: effect of<i>I ³ </i>-irradiation and storage. Journal of Microencapsulation, 2004, 21, 653-665.	2.8	29
81	Poly (D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. Journal of Microencapsulation, 2003, 20, 799-810.	2.8	13
82	Poly (D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: Influence of fatty and non-fatty additives. Journal of Microencapsulation, 2003, 20, 799-810.	2.8	35
83	Comparative study of the dissolution profiles of a commercial theophylline product after storage. Archives of Pharmacal Research, 2001, 24, 568-571.	6.3	2
84	Biodegradable microspheres for vitreoretinal drug delivery. Advanced Drug Delivery Reviews, 2001, 52, 5-16.	13.7	180
85	Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharmaceutical Research, 2000, 17, 1323-1328.	3.5	78
86	Enhancement of the Mydriatic Response to Tropicamide by Bioadhesive Polymers. Journal of Ocular Pharmacology and Therapeutics, 2000, 16, 419-428.	1.4	43
87	Biodegradable poly(DL-lactic-co-glycolic acid) microspheres containing tetracaine hydrochloride. In-vitro release profile. Journal of Microencapsulation, 1999, 16, 105-115.	2.8	16
88	Chronopharmacokinetics and calcium in the prevention of gentamicin-induced nephrotoxicity in rabbits. , 1998, 19, 407-412.		5
89	Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Investigative Ophthalmology and Visual Science, 1997, 38, 665-75.	3.3	46